Although IRF2 positively regulates TP53 function to inhibit HCC growth, it also induces β-catenin expression and inhibits IFN-γ/IRF1 and IRF1/CXCL10/CXCR3 axis to suppress HCC apoptosis, enhance HCC proliferation and resistance to therapeutic drugs (Lenvatinib). This evidence concerns the gene IFNG and hepatocellular carcinoma.